Skip to content

French Version of Fear-Avoidance Component Scale (FACS-FR)

Psychometric Validation of the French Version of the Fear Avoidance Component Scale (FACS)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05217017
Acronym
FACS-Fr
Enrollment
50
Registered
2022-02-01
Start date
2022-02-01
Completion date
2023-02-01
Last updated
2023-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Kinesiophobia

Keywords

Kinesiophobia, Chronic Pain, Fear-avoidance

Brief summary

Chronic musculoskeletal disorders are global burden for economy. Fear-avoidance (FA) seems be a predictor for the transition from subacute to chronic pain. One of the most famous scales to access FA is the Tampa scale of kinesiophobia, but several responders think some items are not clear, too narrow or too general. A new scale, the Fear-Avoidance Components Scale (FACS) was developed by Neblett et al. in 2015 to assess FA. It is a comprehensive set of concepts that more effectively addresses all the essential issues of the FA concept than the current scales. The new scale comprehensively assesses all cognitive, emotional, and behavioral components related to the updated FA model by combining items from well-known scales in the context of the FA model with items on perceived injury-related victimization and blame. A French version of the FACS is currently lacking. The aim of this study is to provide a translation and validation of a French version of FACS in patients with musculoskeletal disorders.

Detailed description

The process is done in two steps to allow the achievement of our two study objectives (translation and validation), with two different cohorts of patients. First, for the French translation of the FACS, a pre-test with a first cohort of 30 patients will be performed. These patients will have to fill in the French version of the paper questionnaire and answer a second one on their interpretation and understanding of the questions. Each question will be evaluated by the patient. A report will be made with the patients' answers to the questionnaire and reported to the translation committee, then modifications will be made to the translation if necessary. If changes are made, a second pre-test will be done until no changes are needed. In a second phase, once the French version is finalized, the second cohort of 50 patients will follow the patient schedule presented in Table I. In more detail, at the initial consultation, the diagnosis of chronic pain should be made by the center's orthopedist. At the same time, the orthopedist, resident, or research assistant will validate, through free and informed consent, whether or not the patient agrees to participate in the study, i.e., T0. At this T0, the patient will have to fill out the four questionnaires, which are FACS, Tampa scale for kinesiophobia French Canadian version (EKT-CF), Pain catastrophizing scale French Canadian version (PCS-CF) and Hospital anxiety and depression scale French version (HADS). The questionnaires will be completed in paper form. At T1, i.e. seven days later, the patient will have to take the FACS French version again on the REDcap platform. This time frame is short enough to allow for a similar or even identical state of function as at T0 for the assessment of test-retest reliability. Patients with a significant change in status will be excluded.

Interventions

DIAGNOSTIC_TESTFACS

Diagnostic Test: Assessment of disability and behavior (by questionnaires)

Sponsors

Université de Sherbrooke
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years old * Current chronic pain complaint is not surgically treated (at least 6 weeks of pain) * Not being currently treated by a physiotherapist for pain complaint * French language is mother tongue

Exclusion criteria

* Pain from a non-musculoskeletal origin (e.g., tumour) * Neurological disease * Impaired cognition

Design outcomes

Primary

MeasureTime frameDescription
FACSday 0The fear-avoidance component scale evaluating fear-avoidance (for all participants) 20 items range from 0-100
TSKday 0Questionnaire evaluating kinesiophobia (for all participants) 17 items total score from 17-68
PCSday 0Pain catastrophizing scale (for all participants) 13 items total score from 0-52
HADSday 0Hospital anxiety and depression scale is a questionnaire evaluating anxiety and depression (for all participants) 2 subscales: anxiety (7 items) and depression (7 items) Total score 0-21 per subscale

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026